GLOW: Zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment for patients with Claudin18. 2+/HER2-Locally advanced unresectable or metastatic gastric …
user-5f8411ab4c775e9685ff56d3（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要